🇺🇸 FDA
Patent

US 10016480

Peptide-based methods for treating pancreatic cancer

granted A61KA61K31/282A61K31/337

Quick answer

US patent 10016480 (Peptide-based methods for treating pancreatic cancer) held by The United States of America as Represented by the Secretary, Dept. of Health and Human Services expires Mon Jul 05 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America as Represented by the Secretary, Dept. of Health and Human Services
Grant date
Tue Jul 10 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 05 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
17
CPC classes
A61K, A61K31/282, A61K31/337, A61K31/4745, A61K31/513